Nicotinic acid impairs assembly of leading edge in glioma cells

Xiangcai Yang1, Shuting Mei2, Hua Niu1

  • 1Department of Clinical Laboratory, The Affiliated Hospital of KMUST, Medical Faculty, Kunming University of Science and Technology, Kunming, Yunnan 650032, P.R. China.

Oncology Reports
|June 29, 2017
PubMed

Insights

Nicotinic acid (NA) shows promise in treating malignant glioma by disassembling F-actin stress fibers crucial for cancer cell migration. This discovery offers a potential new therapeutic strategy for glioblastoma multiforme (GBM).

Area of Science:

  • Oncology
  • Cell Biology
  • Biochemistry

Background:

  • Malignant glioma, particularly glioblastoma multiforme (GBM), is a fatal brain tumor with poor prognosis due to rapid, diffuse invasion.
  • Cancer cell infiltration is a major obstacle for existing glioblastoma multiforme (GBM) therapies.
  • F-actin stress fibers are essential for cancer cell migration, proliferation, and signaling pathways, making them a potential therapeutic target.

Purpose of the Study:

  • To investigate the potential of nicotinic acid (NA) as a therapeutic agent for malignant glioma.
  • To explore the effect of nicotinic acid (NA) on F-actin stress fibers in glioblastoma multiforme (GBM) cells.
  • To evaluate the expression of paxillin in patient-derived glioblastoma multiforme (GBM) samples.

Main Methods:

  • Treatment of HEK293 and NIH3T3 cells with nicotinic acid (NA) to observe F-actin stress fiber disassembly.
  • Application of optimized nicotinic acid (NA) concentrations (3.5 mM and 7.0 mM) to U251 glioblastoma multiforme (GBM) cells.
  • Analysis of F-actin stress fiber disassembly and leading-edge disruption in glioblastoma multiforme (GBM) cells.
  • Immunohistochemical evaluation of paxillin expression in 85 glioblastoma multiforme (GBM) patient paraffin-embedded specimens.

Main Results:

  • Nicotinic acid (NA) treatment led to significant disassembly of F-actin stress fibers in non-cancerous cell lines.
  • Optimized concentrations of nicotinic acid (NA) (3.5 mM and 7.0 mM) detached U251 glioblastoma multiforme (GBM) cells from culture dishes.
  • 7.0 mM nicotinic acid (NA) effectively disrupted the leading-edge assembly in glioblastoma multiforme (GBM) cells.
  • Paxillin expression was detected in 67 out of 85 (approximately 79%) glioblastoma multiforme (GBM) patient samples.

Conclusions:

  • Nicotinic acid (NA) demonstrates a novel function in targeting F-actin stress fibers, impacting cancer cell detachment and leading-edge disruption.
  • The findings suggest that nicotinic acid (NA) could be a potential therapeutic agent for malignant glioma.
  • Paxillin expression in a majority of glioblastoma multiforme (GBM) samples warrants further investigation in conjunction with nicotinic acid (NA) therapy.